Clinical trials have complex eligibility criteria.Always talk to your clinician about you’re interest in participating in a trial.Learn why
HP Version - Clinical trials have complex eligibility criteria.Always talk to your clinician about you’re interest in participating in a trial.Learn why
Optimise reading forHealth ProfessionalsPatients
Closed (no longer recruiting)Last updated: 16 January 2024
Clinical summaryEligibilityParticipating hospitalsSupport
Participants will either receive Dose A (standard dose) or Dose B (higher dose) of belzutifan by oral administration, once a day (QD), until disease progression or discontinuation.
This trial is treating patients with advanced renal cell carcinoma.
Genitourinary
18+
II
MK-6482-013
Use the hyperlinks, where available to access additional clinical trial information.
Merck
Phase 2 Study of MK-6482 in Participants With Advanced Renal Cell Carcinoma
Share with email
Print this page
Download brochure
Clinical trials have complex eligibility criteria.
Ask your doctor if this trial could be right for you.
+ Show non-recruiting hospitals
Tell us if you find this trial availability is not accurate.Report inaccuracy
Speak with someone who has cancer clinical trial experience.
Learn more
If you need cancer information and practical support for yourself, a carer, family or friend, contact Cancer Council’s experienced cancer nurses on 131120.
When you are considering a cancer clinical trial, it is a good idea to discuss it with your family, friends or carers.
Thank you for helping us to increase accuracy of the trial. Our team will validate the information and update the information as soon as possible.